Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EU assesses Regeneron/Roche COVID-19 antibody cocktail for authorisation

10/11/2021 | 09:39am EST

Oct 11 (Reuters) - The European Union's drug regulator said it was evaluating a marketing authorisation for an antibody cocktail developed by Roche and Regeneron for treatment and prevention of COVID-19 in people above the age of 12.

The European Medicines Agency (EMA) said on Monday it will assess the risks and benefits of the drug, called Ronapreve, and it could issue an opinion within two months. The agency has already started a rolling review of the treatment.

Ronapreve has received emergency approval to treat COVID-19 in more than 20 countries including the United Kingdom and United States. It belongs to a class of drugs called monoclonal antibodies that mimic natural antibodies produced by the body to fight off infections.

The EMA said it was assessing clinical data investigating the effectiveness of the drug in preventing hospitalisation in outpatients, and another study looking at effectiveness in preventing COVID-19 in adults and children at risk of infection from a household member diagnosed with the disease.

Gilead's antiviral, remdesivir, is the only COVID-19 treatment that has been approved for use in the European Union.

Marketing authorisation has been submitted for other COVID-19 treatments including Lilly's rheumatoid arthritis drug Olumiant, Sobi's Kineret, Celltrion's regdanvimab and arthritis drug tocilizumab, sold by Roche as RoActemra. (Reporting by Yadarisa Shabong in Bengaluru; Editing by Shinjini Ganguli)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
CELLTRION, INC. -2.59% 207000 End-of-day quote.-42.34%
GILEAD SCIENCES, INC. -2.43% 68.93 Delayed Quote.18.31%
REGENERON PHARMACEUTICALS -2.73% 636.53 Delayed Quote.31.76%
ROCHE HOLDING AG 0.53% 361.6 Delayed Quote.16.39%
All news about REGENERON PHARMACEUTICALS
11/30Officials offer vaccine reassurance; WHO advises against travel bans
RE
11/30US Stocks Slump as Omicron Variant, Fed Chief's Comment on Faster Asset Purchase Taperi..
MT
11/30CLOSE UPDATE : US Stocks See Sharp Decline as Omicron Variant, Fed Chief Comment on Faster..
MT
11/30Yen, Swiss franc rally on global outlook risks after hawkish Powell
RE
11/30ANALYSIS : As Omicron plays havoc with markets, shares of vaccine makers surge
RE
11/30Wall St sinks as taper acceleration worries pile onto virus angst
RE
11/30Pharmaceutical Names to See Increased Volatility into Year End Amid Omicron Updates, Op..
MT
11/30Equities Drop Midday as Moderna CEO Questions COVID-19 Vaccines' Efficacy Against Omicr..
MT
11/30MIDDAY REPORT : US Stocks Drop as Moderna CEO Questions COVID-19 Vaccines' Efficacy Agains..
MT
11/30US Stocks Drop as Moderna CEO Warns on Efficacy of COVID-19 Vaccines Against Omicron; O..
MT
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 15 430 M - -
Net income 2021 7 903 M - -
Net cash 2021 5 814 M - -
P/E ratio 2021 9,10x
Yield 2021 -
Capitalization 66 553 M 66 553 M -
EV / Sales 2021 3,94x
EV / Sales 2022 4,41x
Nbr of Employees 9 766
Free-Float 81,9%
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 636,53 $
Average target price 697,52 $
Spread / Average Target 9,58%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS31.76%66 553
GILEAD SCIENCES, INC.18.31%86 465
BIONTECH SE331.48%84 953
WUXI APPTEC CO., LTD.28.27%66 734
VERTEX PHARMACEUTICALS-20.90%47 530
BEIGENE, LTD.34.50%32 613